Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP

By sjmartinez • May 7, 2024

Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, Landovitz RJ, Delany-Moretlwe S, Marzinke MA, McKeon T, Budnik P, van Wyk J, Ford SL. Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. Antimicrob Agents Chemother. 2024 May 6:e0147523. doi: 10.1128/aac.01475-23. Epub ahead of print. PMID: 38709006.

Tags: Cabotegravir, HIV, Infectious Diseases, oral lead-in, Pharmacokinetics, Pre-exposure prophylaxis, Publications

Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings

Joseph Davey D, Dadan S, Wara N. Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings. Curr Opin HIV AIDS.[...]

Lessons learned from COVID-19 to overcome challenges in conducting outpatient clinical trials to find safe and effective therapeutics for the next infectious pandemic

Oh MA, Currier J, Khan A, Mylonakis E, Newell M, Ignacio RB, Jilg N, Safdar B, Merck LH, Smith DM. Lessons learned from COVID-19 to[...]

ACTIV trials: cross-trial lessons learned for master protocol implementation

Keshtkar-Jahromi M, Adam SJ, Brar I, Chung LK, Currier JS, Daar ES, Davey VJ, Denning ET, Gelijns AC, Higgs ES, Jagannathan P, Javan AC, Jensen[...]